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Several actin-binding proteins have been shown to be altered in metastat ic cell lines and tumours and, in 
particular, Myristoylated Alanine-Rich protein Kinase C substrate (MARCKS) has been implicated in the 
pathogenesi s of various highly metastatic epithelial malignancies. Considerin g that a large percentage 
of deaths due to colorectal cancer (CRC) are consequent to hepatic metastasization, aim of this study 
was to elucidate the involvement and mechanism of MARCKS in CRC by employing in vitro and in vivo 
approache s. Loss-of and-gain-on function approaches of MARCKS were employed in two human CRC cell 
lines: Clone A cells expressing MARCKS and LoVo cells known to have a frameshift mutation of MARCKS 
i.e. typically for MSI-H CRC. The data unveiled that altering MARCKS expression suppresses cell motility 
and invasion in human colon carcinoma cells when conditioned medium of liver-specific stromal cells 
(hepatic stellate cells) was used as chemoattractant. Depletion or re-expression of MAR CKS inhibited pro- 
liferati on with a reduction in expression of the mitotic regulator Aurora B kinase (AURKB), whereas 
AURKB -depletion did not modify MARCKS expression. In murine colon carcinoma CT26 cells, shRNA 
MARCKS-d epletion reduced motility and invasion, and induced an aberrant, prolonged mitotic process.
Significantly less metastases were produced in a syngenei c model of colon metastasis by MARCKS- 
depleted CT26 in comparison to CT26-tumour challenged mice. In conclusion, MAR CKS plays an articu- 
lated role in the progression of colorectal cancer and might represent a suitable target to interfere and 
overcome the invasive behaviour of colon carcinoma cells at primary and distant sites.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction 
Tumour growth and progression is not entirely due to genetic 
aberrations but also reflective of tumour cell plasticity. To metasta- 
size, tumour cells must achieve a higher cell membrane plasticity 
and motion which are largely driven by the actin cytoskeleton 
and relies on the actin-based cytoskeleton reorganizati on [1]. Actin 
is the major constituent of the microfilament system and shows a
high degree of structural plasticity. This plasticity is provided by 
the interplay between the monomeric , oligomeri c and polymeric 
forms of actin and specializ ed actin-binding proteins that control 
the polymerisation and de-polymer isation of actin [2]. Several of these actin-binding proteins are up- or down-regulated in meta- 
static cell lines and tumours. In particular , recent studies have 
identified Myristoylat ed Alanine-Ric h C Kinase Substrate 
(MARCKS) to be implicate d in the pathogenesis of various malig- 
nancies such as pituitary and thyroid cancer [3], breast cancer 
[4], melanoma [5], glioblastoma multiform e cancer [6,7], and chol- 
angiocarci noma [8].
Overall, the function of MARCKS in these malignancies seems to 
be multiface ted and depends on cell type and tumour origin. The 
identification of MARCKS as a frequent target of mutation in colo- 
rectal carcinomas and small intestinal adenocarci nomas with MSI- 
H [9–11] certainly adds more complexity to the involvement of 
MARCKS in tumour formatio n. Indeed, the observed mutation in 
the effector domain of MARCKS, which contains the actin bindings 
domains, [12,13] may lead to an aberrant re-organization of the ac- 
tin cytoskeleton affecting processes such as motility, invasion and 
prolifera tion. A defect in the actin cytoskeleton architecture could 
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regulation or localization of the mitotic regulator AURKB has been 
linked to genomic instability, tumourigenes is, tumour progression ,
and poor prognosis in a wide variety of cancer types including CRC 
[14–16]. Along these lines, we have previously demonstrated a
close interaction between MARCKS and AURKB during mitosis. In 
particular, the specific cellular distribut ion of AURKB during the 
different mitotic steps depends on the presence of MARCKS and 
MARCKS regulation of actin filament formation [17].
Overall, the functional role of MARCKS during colorectal tumour 
progression and metastasizatio n is largely unknown. Therefore, the 
aim of the present study was to investiga te the functiona l role of 
MARCKS in vitro , by performi ng gain-on and-of experiments in 
CRC cell lines and in vivo by using a syngeneic murine model of li- 
ver metastasis.
2. Materials and methods 
2.1. Reagents 
Antibodies against alpha-smooth muscle actin (a-SMA) (mouse ascites, clone 
1A4), b-actin (AC-15) and anti-actin (rabbit, 20–33) and all reagents used in this 
study are from Sigma Aldrich (Saint Louis, MI) or otherwise mentioned. Antibodies 
against AURKB (AIM-1) were purchased from Sigma (rabbit, A5102) or BD Trans- 
duction Laboratories (mouse, AIM-1). Primary antibodies against MARCKS (N-19
and M20), P-MARCKS (Ser159/163), a-tubulin (H-300) were purchased from Santa 
Cruz Biotechnology as well as their secondary antibodies, respectively HRP-conju- 
gated goat or rabbit IgG. All antibodies were used according to the manufacturer’s 
manual.
2.2. Cells and cell culture 
All cell lines were obtained from American Type Culture Collection (Manassas,
VA) and were cultured in RPMI completed with 2 mM/L glutamine, 1.0 mM/L so- 
dium pyruvate and supplemented with 10% Foetal Bovine Serum (FBS) (all provided Fig. 1. MARCKS and AURKB expression in human colon cancers, Clone A cells and LoVo c
MARCKS protein expression was compared between LoVo cells and Clone A cells. Re
expression patrons for MARCKS and AURKB were assessed by QRT-PCR. The expression wa
vs normal paired colon tissue (N), and two patients with Stage IV liver metastasis tumour
tissue).by GIBCO Laboratories, NY). Human hepatic stellate cells (hHSCs) were isolated 
from wedge sections of normal human liver unsuitable for transplantation, as 
extensively described elsewhere [18]. Cells were cultured in Iscove’s Modified
DMEM supplemented with 0.6 U/ml insulin, 2 mM/L glutamine, 0.1 mM/L non- 
essential amino acids, 1.0 mM/L sodium pyruvate and 20% FBS. Harvesting the con- 
ditioned medium of hHSC (hHSC-CM) was performed at passage 5. At these stage,
cells show functional and ultrastructural features of fully activated HSC [19]. Mice 
(mHSC) were isolated from liver Balb/c mice followed by density gradient centrifu- 
gation and culturing conditions as mentioned before. Conditioned medium of acti- 
vated hHSC-CM and mHSC (mHSC-CM) was harvested after 48 h of incubation in 
serum-free medium. All cell lines were cultured under standard conditions in a
humidified incubator under 5% CO 2 in air at 37 C.
Conditioned medium from human or murine HSC was employed as a specific
stimulus for CRC cell migration and invasion assays. This choice was based on pre- 
vious published evidence indicating that activated HSC produce and secrete soluble 
factors and chemokines that promote a pro-inflammatory microenvironment, tis- 
sue angiogenesis and tumour progression. Therefore, activated hHSC favour the 
‘‘homing’’ of tumour cells in the liver microenvironment [20–22]. Hence, the condi- 
tioned medium of activated hHSC is as an excellent and specific tool to investigate 
the possible cross-talk between cancer cells and hHSC during chemotaxis.2.3. Protein extraction, immunoprecipitation and Western blot analysis 
For immunoblot analysis whole cell lysates were separated on SDS–PAGE,
transferred to nitrocellulose, and immunoblotted as described previously [23]. An 
antibody against a-SMA, total actin, a-tubulin or PCNA was used to demonstrate 
equal loading.2.4. RNA interference and plasmid transfection 
Transient gene silencing : in Clone A cells was performed by using human 
MARCKS validated SMARTpool siRNA (M-004772-00). RNAi against human AURKB 
in Clone A cells and LoVo cells was performed by using validated SMARTpool siRNA 
(M-003326-02) (Custom SMARTpool siRNA Design Service of Dharmacon, Lafayette,
CO). For transient transfection, siLentFect™ Lipid Reagent (BioRad Laboratories, CA)
was employed. Briefly, 3  105 cells were cultured per 6-well plate. After 24 hells. (A) MARCKS RNA expression was determined in LoVo cells vs Clone A cells. (B)
presentative of at least three independent experiments. (C and D) Different RNA 
s compared between three patients classified in Stage I colon carcinoma, tumour (T)
 (T) vs normal paired liver tissue (N) (P < 0.005 vs normal tissue, P < 0.05 vs normal 
Fig. 2. RNAi of MARCKS in Clone A cells inhibits cell migration and invasion. (A)
Boyden chamber chemotaxis assay was performed using as chemoattractant the 
conditioned medium (CM) of human hepatic stellate cells (hHSCs-CM). Values are 
expressed as cells migrated per High Power Field (HPF) and are shown as mean ± SD 
of four independent experiments. P < 0.05, vs scrambled control cells towards 
hHSC-CM. (B) Invasion Matrigel assay was performed using hHSC-CM as chemo- 
attractant. Values are shown as mean ± SD of four independent experiments.
P < 0.05, vs scrambled control cells towards hHSC-CM. (C) The reduced chemotaxis 
of MARCKS-depleted Clone A cells towards hHSC-CM coincides with morphological 
changes.
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and added to the cells. Scrambled control siRNA was used in every transfection 
experiment [23].
Stable gene silencing : Murine colon carcinoma CT26 cells were stable transfected 
with murine validated short Hairpin RNA (TR512267, 4 shRNA constructs with 
puromycin cassette, containing two control shRNA) (OriGene Technologies, MD).
Briefly, 3  105 cells were cultured in a 6-well plate and after 24 h cells were trans- 
fected with 1 lg/3 ml of shRNA construct using the Mirus 2300 Trans-IT-LT1 trans- 
fection reagent (Mirus Bio LLC, WI) and 8 ll/ml of puromycin was added to the 
medium. Single cell colonies were selected and experiments were performed on 
single cell colonies of the 4th generation.
MARCKS plasmid transient transfection assay : LoVo cells were transiently trans- 
fected with a human MARCKS plasmid (WT-PJ7) or empty vector using the Lipofect- 
AMINE reagent (Life Technologies, Invitrogen). Furthermore, two different MARCKS 
cDNA mutations were investigated: (1) a myristoylated mutant (PJ7-G1A, Myr-m)
where the N-terminal glycine was replaced by an alanine that is unable to insert 
MARCKS protein into the plasma membrane but still contains the functional do- 
main, and (2) a deletion mutant of the PSD (PJ7-PSD, PSD-m) which is replaced 
by Proline–Glycine. All plasmids were kindly given by Dr. S. Manenti (INSERM, Tou- 
louse Cedex, France) [5,24]. Functional experiments were performed 48 h after each 
transfection and the transfection efficiency was evaluated by employing protein- 
and RNA analysis.
2.5. Boyden chamber assays 
Briefly, Boyden chambers were equipped with 8- lm pore filters Poretics (Liver-
more, CA) and coated with rattail collagen (Collaborative Biomedical Products, MA)
or Matrigel as previously described [20,23]. After employing gain-on or gain-of 
studies against MARCKS, cells were trypsinized and re-suspended in serum-free 
medium at a concentration of 6  104 cells/200 ll and added to the upper Boyden 
chamber. The conditioned medium of human HSC (hHSC-CM) or mouse HSC 
(mHSC-CM) was used as chemoattractant depending on the cell line species under 
investigation. After overnight incubation, the cells migrating to the underside of the 
filters were fixed, stained with Giemsa, mounted and viewed at 40  magnification.
Data are the average of cell counts obtained in 10 randomly chosen high-power 
fields (HPF).
2.6. RNA isolation and QRT-PCR 
Total RNA was isolated with NucleoSpin RNAII (Macherey Nagel) according to 
the manufacturer’s manual and 0.4 lg aliquots were reverse-transcribed with ran- 
dom primers using a Reverse Aid M-MuLV reverse transcription kit (Fermentas).
Target cDNA levels were quantified by SYBRE green-based RT-PCR using specific
Taqman gene expression-assays (Applied Biosystems) with supplied probes on a
Rotor Gene 6000 (Corbett Research).
Expression data from three male patients with colon rectal cancer and paired 
tissue classified in Stage I (T2, N0, MX), and two patients classified in Stage IV 
(TX, NX, M1) was generated from total RNAs obtained from OriGene Technologies 
(CR561166-CR561168, CR56277-CR562676, CR562687-CR562700, CR559462- 
CR563007, CR560798-CR560801). Additional sample information and pathology re- 
ports are available on Origene Technologies website. Measured mRNA levels were 
normalized to those of b-actin or GAPDH as internal control and performed in trip- 
licate. The relative levels of RNA were determined using the efficiency-corrected
threshold cycle (DCT) method.
2.7. In vivo liver metastasis assay 
Experimental protocols were conducted according to established international 
guidelines and with the approval of the National Regulatory Authorities and insti- 
tutional guidelines. Six week old BALB/c mice (20 g, Charles River Laboratories,
Italy) were tumour-challenged employing an intrasplenic bolus injection of scram- 
bled control CT26 cells or MARCKS shRNA-depleted CT26 cells (5  104/50 ll
PBS1X). Sham-operated mice were obtained by performing the same surgical oper- 
ation and injected with vehicle. Each group contained five animals. As was empir- 
ically proven, all CT26-tumour challenged mice developed liver metastasis. Mice 
were sacrificed after 23 days. Liver tissue was taken, snap-frozen or fixed in 10%
buffered formaldehyde and embedded overnight in paraffin. This was followed by 
a standard haematoxylin-eosin staining as described previously [17].
2.8. Cell proliferation assays 
MTT assay : scrambled control cells and shRNA MARCKS-depleted CT26 cells 
were seeded into a 12-well culture plate at 4  104 cells per well, performed in 
6-fold for each condition. Proliferation was measured by employing the MTT assay 
with key component 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra zolium bro- 
mide (MTT) according to the manufacturer’s manual (Sigma Aldrich).
DNA synthesis : DNA synthesis was measured as the amount of [3H] TdR incor- 
porated into trichloroacetic acid-precipitable material, as described elsewhere 
[25]. Methyl-[3H]-thymidine was from New England Nuclear (Milan, Italy).Cell count : after 48 h of transient transfection cells were trypsinized, stained 
with Trypan blue and counted.
2.9. Video time lapse imaging 
To determine the impact of MARCKS expression on cell cycle, time lapse micros- 
copy was employed that enables tracking of cell cycle progression at the single cell 
level [17] Video microscopy was performed by culturing cells in a micro-incubator 
(Pecon) with controlled humidity, temperature and CO 2, mounted on inverted Leica 
AM6000 microscope with fully motorized stage. ShRNA MARCKS-depleted CT26 
cells and scrambled control cells were followed over 24 h. Experiments were per- 
formed acquiring multiple fields of view for each experimental condition by using 
oblique illumination and a 20X air objective. Multi-field acquisition was done using 
Leica LasAF software. Image analysis was performed by Image J software and Adobe 
PhotoShop.
Duration time of mitosis (DTM): mitotic entry was scored by the first image 
showing extensive cell rounding and is defined as the time (start t0), whereas mi- 
totic exit was scored as the last image showing the pinching-off of the two daughter 
cells [17,26–28]. The duration time of mitosis was measured for each mitotic cell in 
both conditions thus calculating the total sum of the DTM and the average DTM. Er- 
ror bars represent standard error. The obtained average DTM of scrambled control 
cells (marked as t) was used as a cut-off value and compared with the DTM in 
MARCKS-depleted cells (marked as >t).
2.10. Statistical analysis 
The statistical differences were determined by unpaired two-tailed Student’s t
test. Two groups were considered statistically significant when P value was less 
than 0.05 or 0.005 as mentioned in the figure legends.
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3.1. The expression profile of MARCKS and AURKB in human colon 
carcinoma cell lines and in surgical specimens 
In a first set of experiments, mRNA and protein expression of 
MARCKS were investigated in two different human colorectal car- 
cinoma cell lines by employin g QRT-PCR and Western blot, respec- 
tively. Clone A cells were originally isolated from a poorly 
differentiate d human colon adenocarcinoma, whereas LoVo cells 
are defined as a DNA mismatch repair (MMR) deficient cell line,
expressing a frameshift mutation for MARCKS inducing a truncated 
protein [9,10].
MARCKS mRNA expression in LoVo cells was detectable but at 
an extreme low level (<0.001 arbitrary units) when compare d to 
MARCKS mRNA expression in Clone A cells (Fig. 1A). Analysing 
the protein expression level of MARCKS in both cell lines revealed 
that LoVo cells do not express MARCKS protein, whereas MARCKS 
was abundantly present in Clone A cells (Fig. 1B).
These in vitro findings suggest that MARCKS expression could be 
characterized by high variabilit y in different colorectal carcinom as.
This was also suggested by evidence obtained by investigatin g
mRNA expression of MARCKS and AURKB in surgical samples of 
human colon carcinoma. A total of five paired samples from indi- 
vidual cases of CRC were investigated . Three of these samples were 
from patients classified in Stage I (T2, N0, MX) while two samples 
were from patients classified in Stage IV (TX, NX, M1) based on 
their case ID reported by OriGene Technologie s. As shown in 
Fig. 1C, the mRNA expression level of MARCKS was strongly up- 
regulated in tumour vs normal tissue in one sample classified Stage 
I while no differenc e was observed in the resulting two samples.Fig. 3. The actin binding potential of MARCKS limits migration in LoVo cells. (A) MARCKS
with empty vector and compared with LoVo cells transfected with a human MARCKS plas
a MARCKS myristoylated cDNA mutant (Myr-m). (B) Western blot analysis demonstrate
Boyden chamber chemotaxis assay using hHSC-CM as chemoattractant. Values are sh
#P < 0.05, vs MARCKS-WT. Wild type MARCKS transfected LoVo cells changed cell morpho
Invasion Matrigel assay was performed using hHSC-CM as chemoattractant. Values are MARCKS expression showed to be up-regulate d in one sample clas- 
sified in Stage IV tumour vs normal liver tissue, whereas MARCKS 
expression level did not varied between tumour and normal tissue 
in one sample. Aurora kinase B mRNA expression was up-regulated 
in tumour vs normal tissue in all Stage I samples (Fig. 1D). In two 
samples classified in Stage IV, AURKB expression showed to signif- 
icantly be up-regulated only in one out of two cases.3.2. Loss of function of MARCKS interferes with cell motility and 
invasion in Clone A cells 
In this group of experiments we investigated whether changing 
MARCKS protein expression, and therefore the actin cytoskeleton ,
could affect cell migration and invasion of Clone A cells when con- 
ditioned medium of activated hHSC (hHSC-CM) was used as che- 
moattractan t [20–22]. Therefore, RNAi against MARCKS was 
performed , followed by modified Boyden chamber migration-and 
invasion assays. As shown in Fig. 2A, cell motility of scrambled 
control cells was induced by hHSC-CM, whereas migration of 
MARCKS- depleted cells was significantly reduced.
A similar pattern of invasion was obtained when MARCKS- 
depleted Clone A cells were challenged to invade a modified
Boyden chamber coated with Matrigel. Invasion of scrambled 
control cells was induced by hHSC-CM, whereas it was strongly 
inhibited in MARCKS-depleted cells (Fig. 2B).
The observed inhibition in chemotaxis towards hHSC-CM, known
to be a strong hepatic chemoattractant [20–22], coincides with evi-
dent morphological changes. Scrambled control cells showed a more
epithelial phenotype, whereas MARCKS-depleted Clone A cells were
characterized by mesenchymal-like features (Fig. 2C). RNA expression levels were assessed by QRT-PCR in parental LoVo cells transfected 
mid (WT), a MARCKS cDNA mutant of the phosphorylation site domain (PSD-m), and 
s the transfection efficiency. (C) Mutational analysis was performed followed by a
own as mean ± SD of two independent experiments. P < 0.005, vs empty vector,
logy in comparison to control cells when hHSC-CM was used as chemoattractant. (D)
shown as mean ± SD of two independent experiments, P < 0.05, vs empty vector.
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Next we investiga ted whether cell motility was affected by re- 
expressing MARCKS in LoVo cells which do not normally express 
MARCKS protein. LoVo cells were transfected with a wild type 
(WT) MARCKS plasmid and two different MARCKS cDNA harbour- 
ing mutations i.e. a myristoylated mutant (Myr-m) and a deleted 
mutant of the PSD (PSD-m). As shown in Fig. 3A and B, MARCKS 
mRNA and protein expression were detectable in all three different 
cDNA transfected cellular conditions but not in parental empty 
vector transfected cells. In addition, phosphoryla ted MARCKS was 
detectable in WT and Myr-m transfected cells, whereas the PSD- 
m transfected cells were negative for phosphoryla ted MARCKS,
confirming that the phospho rylation site domain of MARCKS is 
mutated (Fig. 3B).
Migration of LoVo cells transfected with WT MARCKS and mu- 
tated variants revealed a remarkabl e reduction in cell motility 
(Fig. 3A). These findings indicate that the re-express ion of MARCKS 
in LoVo cells affects the actin cytoskeleton reorganizati on during 
migration and that both the phosphorylatio n and the myristoyl a- 
tion of MARCKS are of equal importance for MARCKS proper cy- 
cling between the cytosol and the plasma membrane in order to 
regulate cell motility. Interestingl y, LoVo cells that migrated to- 
wards hHSC-CM changed morphology when MARCKS expression 
was re-expressed. Empty vector-transfected cells showed mesen- 
chymal-like features whereas LoVo cells transient transfected with 
MARCKS cDNA WT featured an epithelial phenotype (Fig. 3C). The Fig. 4. Changing MARCKS protein expression affects cell proliferation. Interplay betwee
reduction in cell proliferation as measured by Methyl-[ 3H]-thymidine incorporation into D
were trypsinized, stained and cell number was counted. MARCKS re-expression inhibits 
depleted Clone A cells and MARCKS WT cDNA-transfected LoVo cells affect AURKB prote
expression. Western blot analysis demonstrates the effect of RNAi against AURKB in Clo
independent experiments, P < 0.005).re-express ion of MARCKS and cDNA mutants resulted in an even 
higher inhibitory effect on the invasive capacity of LoVo cells.
Empty vector transfected control cells invaded the Matrigel-co ated 
filter, whereas all transfected LoVo cells did not invade (Fig. 3D).
Overall, these data demonstrat e that MARCKS acts as a key regula- 
tor of cell motility.3.4. MARCKS affects AURKB expression in Clone A cells and LoVo cells 
In a previous study we demonstrated that MARCKS is important 
for proper mitosis and that RNAi against MARCKS results in a pro- 
longed cell cycle and AURKB delocalization [17]. In this study the 
effect of changing MARCKS protein expression on proliferation 
was analysed. Moreove r, a possible link between MARCKS and 
AURKB in Clone A and LoVo cells was investigated .
RNAi against MARCKS expression in Clone A cells and re- 
expression in LoVo cells inhibited cell prolifera tion (Fig. 4A). The 
inhibitory effect of changing MARCKS expression on cell prolifera -
tion coincided with a down-regul ation of AURKB protein expres- 
sion in both cells lines as shown in Fig. 4B. Next, in two 
independen t experiments, Clone A and LoVo cells were silenced 
against AURKB and western blot analysis showed that MARCKS 
protein expression was not affected when Clone A cells were si- 
lenced against AURKB (Fig. 4C). This finding suggests that an actin 
filament binding protein such as MARCKS can affect AURKB protein 
synthesis , but AURKB does not reciprocally affect MARCKS protein 
expression.n MARCKS and AURKB. (A) RNAi against MARCKS in Clone A cells coincides with a
NA (n = 3, P < 0.05 vs scrambled control). MARCKS WT cDNA-transfected LoVo cells 
cell proliferation (n = 3, in duplicate, P < 0.05, vs vector control cells). (B) MARCKS- 
in expression. (C) AURKB-depletion in Clone A cells does not affect MARCKS protein 
ne A cells and LoVo cells (a representative picture and histogram is shown of two 
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invasion in vitro 
The effect of MARCKS-depleti on was assessed in the murine 
CT26 colon carcinoma cell line in a group of in vitro experiments
instrumenta l for setting an in vivo model of liver metastasiza tion.
As shown in Fig. 5A, CT26 cells were stable shRNA transfected 
against MARCKS and cell migration and invasion were investi- 
gated. Stable shRNA MARCKS-depleted cells showed a decrease 
in cell motility in comparison to shRNA scrambled control cells to- 
wards mHSC-CM (Fig. 5B). As shown in Fig. 5C, cellular invasion of 
shRNA-trea ted MARCKS cells was reduced in comparison to scram- 
bled control cells when mHSC-CM was used as chemoat tractant.3.6. MARCKS depletion delays duration time of mitosis in CT26 cells 
Previous experimental evidence provided by our group sug- 
gested a key role of MARCKS in regulating the actin cytoskeleton 
during cell cycle in primary hHSC [17]. In this set of experiments 
the different phases of cell division of MARCKS-de pleted CT26 cells 
and shRNA scrambled control cells were monitored by oblique- 
illumination video time lapse-imaging and this to investigate the 
role of MARCKS during mitosis in neoplastic cells such as CT26 
cells. More specifically, the duration time of mitosis (DTM) of each 
mitotic cell was measured. Stably MARCKS-de pleted CT26 cells 
showed a clear difference in phenotype during interphase in com- 
parison to the scrambled shRNA control cells. These cells showed 
the typical epithelial phenotype whereas shRNA MARCKS-depleted 
cells showed a mesenchymal-l ike phenotype (Fig. 6A). ShRNA- 
MARCKS-de pleted cells were inhibited in proliferation when mea- 
sured by employin g MTT assay (Fig. 6B). Next, scrambled control 
cells showed an average DTM of 160 min (n = 54, Fig. 6C and Sup-
plementary Video 6.1 ), whereas mitotic shRNA MARCKS-de pleted 
cells are characterized by a significant increase in DTM when com- 
pared to scrambled control cells (n = 43, Fig. 6D and Supplemen-
tary Video 6.2 ). These data demonstrat e that more than 51.2% of 
this cell population is characterized by a marked increase in DTM 
when compared with the average DTM of scrambled control cells 
(Fig. 6E). This feature coincided with an aberrant formation of 
the cleavage furrow followed by a delay in cleavage furrow ingres- 
sion and pinching-of f of the two daughter cells (Supplement ary 
Video 6.2 and 6.3 ). In parallel, MARCKS protein expression was 
analysed by Western blot analysis (Fig. 6F).Fig. 5. Down-regulation of MARCKS expression inhibits migration and invasion of 
CT26 in vitro . (A) Western blot analysis showed the transfection efficiency of CT26 
cells stable shRNA-depleted for MARCKS with different shRNA MARCKS (constructs
1–3), shRNA-C is empty vector and shRNA-SC is the scrambled control. (B) A Boyden 
chamber chemotaxis assay was used with mHSC-CM as chemoattractant. Values are 
shown as mean ± SD of three independent experiments. P < 0.005 vs shRNA 
scrambled control. (C) Invasion Matrigel assays were performed using mHSC-CM as 
chemoattractant. Values are shown as mean ± SD of three independent experi- 
ments. Invasion was reduced when mHSC-CM was used as chemoattractant.
P < 0.005 vs shRNA scrambled control cells.3.7. Down-regula tion of endogenou s MARCKS in CT26 cells 
antagonizes the metastati c ability in vivo 
A CT26 murine colorectal liver metastas is assay, syngenei c to 
BALB/c mice, was performed in vivo to compare tumour formatio n
between CT26 scrambled control cells and MARCKS-sh RNA treated 
cells. Stable shRNA-tran sfected CT26 cells were used in these 
experiments and western blot analysis showed a strong reduction 
in MARCKS protein expression as shown in Fig. 7A. When mice 
were tumour-challe nged, the suppression of MARCKS protein 
significantly decreased metastati c burden compared to the CT26- 
tumour challenged mice (Fig. 7B). Liver metastas is in CT26 
tumour-chal lenged mice demonst rated to contain 5–15 multiple 
macroscopic nodules occurring in a single liver (Fig. 7C). In 
contrast, few or no metastas es were found macroscopicall y on 
the surface of the liver of those mice that were tumour-chal lenged 
with CT26 shRNA-depl eted of MARCKS (Fig. 7B). This was con- 
firmed by histology examination of performi ng haematoxyl in- 
eosin stained sections (Fig. 7D). In contrast to the liver, tumour 
formation was found at the primary site of injection , i.e. spleen,
in both conditions under investiga tion (Fig. 7B). These data confirmthe previousl y observed inhibitory effect of MARCKS depletion on 
cell migration and invasion in vitro.
4. Discussions 
MARCKS, a major PKC substrate, has been shown to be involved 
in the tumourig enesis of pituitary and thyroid tumours, breast can- 
cer, cholangioca rcinoma and in glioblastom a multiforme. Altera- 
tions in the PKC-MARCKS- actin axis have been shown to affect 
processes such as motility, proliferation, invasion, adhesion, cell 
spreadin g and membran e trafficking [3,7,8,29 ]. Moreover, recent 
studies have identified MARCKS as a frequent target of mutation 
in colorectal carcinom as and small intestinal adenocarcinom as 
with MSI-H [9–11]. Overall the fine molecular mechanism s
through which MARCKS affects tumour progression during CRC 
developmen t are largely unknown.
The reorganizati on of the actin cytoskeleton is defined as the 
primary mechanism of cell motion during migration and cell inva- 
sion that is orchestrated by actin filament binding proteins such as 
Fig. 6. Down-regulation of MARCKS protein delays duration time of mitosis in CT26 cells. (A) Phase contrast imaging shows that shRNA MARCKS-depleted cells obtain a
mesenchymal-like phenotype during interphase in contrast to the epithelial-like morphology observed in scrambled control cells. (B) A down-regulation in MARCKS protein 
expression inhibits cell cycle as was measured by MTT assay (two independent experiments performed each in 6-fold). Values are shown as mean ± SD, P < 0.005 vs
scrambled control. (C) A Montage of live cell imaging of shRNA scrambled control cells. Numbers in images indicate time (in minutes) since entering in mitosis. (D) Snapshots 
of a montage shows that shRNA MARCKS-depleted cells are marked with a delay in DTM that coincides with a morphological aberrant phenotype of the two daughter cells. (E)
shRNA MARCKS stable transfected cells show a significant increase in the duration time of mitosis (DTM) when compared to scrambled control cells (sum of DTM, values are 
shown as mean ± SD, P < 0.005 vs scrambled control). Scrambled control cells have an average DTM of 160 min (marked as t time = 100%) whereas 51.2% of MARCKS 
depleted cells have a delay in DTM (marked as >t) (n = 3). (F) Representative Western blot analysis shows the absence of MARCKS protein expression in stable transfected 
shRNA MARCKS-depleted cells (n = at least 3).
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role of MARCKS in the modulation of platelet-derive d growth fac- 
tor (PDGF)-induced hHSC motility [23]. These cells are liver-spe- 
cific multifunctional mesenchym al cells known to play a key role 
in human liver pathophysiol ogy [30–32], including a distinct stro- 
mal contribution to the developmen t to primary and metastatic li- 
ver cancers [20–22]. In the present investigatio n we demonstrat e
that colon cancer cell motility and invasion in response to an estab- 
lished stromal extracellular stimulus, i.e. HSC-CM, are strongly af- 
fected by modulating MARCKS expression. Indeed, by altering intracellul ar MARCKS expression and therefore actin cytoskeleton 
dynamics , the effect of HSC-CM was abolished in both human 
and murine colorectal carcinom a cell lines. These changes are re- 
lated to modifications of the fine-tuned balance between actin 
and MARCKS regulating reversibl e and local protein-mem brane 
interactio ns ensuring cell plasticity, polarity and surface charge 
[33–35] in response to extracellular stimuli. Exogenous over- 
expression of MARCKS and mutational gain-on experiments re- 
vealed that MARCKS is an important determinant of cell motility 
and that the myristoylated domain and the phospho rylation site 
Fig. 7. The effect of MARCKS-depletion in CT26 cells attenuates tumour progression in vivo . (A) Representative Western blot analysis shows the stable transfection efficiency
of shRNA against MARCKS in CT26 cells. (B) Photographs of representative liver after performing a colorectal liver metastasis assay in vivo . In both conditions, tumour 
formation was observed in the intrasplenic injection site, whereas hepatic metastases were detectable in SCRNA CT26 tumour-challenged mice with few or no tumour 
formation in MARCKS-depleted CT26 cells tumour-challenged mice. (C) Graphs show the body–liver weight (%) and demonstrates a significant induction of CT26 and 
MARCKS-depleted CT26 tumour-challenged mice vs sham-operated (P < 0.05, vs sham-operated mice). Tumour-challenged mice with shRNA MARCKS-depleted CT26 cells 
showed few or no metastases in comparison to CT26 tumour-challenged mice (P < 0.005 vs shRNA SC). (D) Haematoxylin-eosin staining confirmed the presence of hepatic 
tumours in CT26 tumour-challenged mice.
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membrane actin cytoskeleton during migration.
In addition to colon cancer cell motility and invasion, MARCKS 
expression may have also relevant implication on the cell cycle,
as suggested by several studies [5,36,37]. Since mitosis is charac- 
terized by a dynamic remodelling of the cortical actin network 
[38,39], the relationshi p between MARCKS, a key factor in actin 
reorganizati on, and AURBK, an important key mitotic checkpoint 
[15,40], was further investigated. Changes in MARCKS protein 
expression, and thus the actin cytoskeleton , led to modifications
in AURBK expression as shown by gain-on and gain-off experi- 
ments in both Clone A cells and LoVo cells. These data suggest that 
the re-organ ization of the actin cytoskeleton has a major impact on 
mitotic regulators such as AURKB, in agreement with recent data 
from our group [17].
The relationship between MARCKS expression and colon cancer 
cell biology was further confirmed in CT26 murine colon carci- 
noma cells in experiments preparator y to the establishment of 
the syngeneic in vivo model. Depletion of MARCKS resulted in re- 
duced cell motion and prolonged cell cycle time suggesting a pos- 
sible inhibitory effect on tumour growth at the metastatic site.
Indeed, mice tumour-chal lenged with control cells developed a lar- 
ger number of liver metastases when compared with mice tumour- 
challenged with MARCKS-de pleted cells thus confirming that 
MARCKS affects tumour progression in vivo. Altogether, the 
in vitro and in vivo observations obtained by MARCKS-depleti on 
in CT26, may recapitulate the clinical-pathol ogical characterist ics 
of MSI-H CRC, a CRC subtype which is characterized by unique 
molecular features and has distinct and relatively unknown mech- anisms by which colorectal cancer arise [41]. MARCKS activity has 
been shown to be impaired in MSI-H CRC as a consequence of a
frameshift mutation and, although MSI-H CRC are poorly differen- 
tiated, they tend to be associated with a better patient survival 
prognosis [42] also in reason of a significantly lower rate of distant 
metastas es [43]. An additional or alternative MARCKS- related 
mechanis m explaining the reduced incidence of metastasis in this 
type of CRC is the immune reaction elicited by the secretion of a
frameshift-m utated protein conseque nt to the mutation of 
MARCKS and recognized as an antigen characterized by a high 
immunog enic potential [9,44,45].
Taken together, the results of the present study delineate a
complex and articulated role of MARCKS in the progression of colo- 
rectal cancer. MARCKS supports colon cancer cell motility, invasion 
and proliferation whereas lack of MARCKS markedly affects these 
cancer features and reduces metastasizatio n. Consequentl y,
MARCKS might represent a suitable target to interfere and over- 
come the invasive behaviour of colon carcinoma cells at primary 
and distant sites.
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